SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
5-year follow-up of SEQUOIA trial showed zanubrutinib maintained superior progression-free survival over bendamustine plus rituximab in untreated CLL/SLL patients, with no new safety signals.
Highlighted Terms
Related News
SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
5-year follow-up of SEQUOIA trial showed zanubrutinib maintained superior progression-free survival over bendamustine plus rituximab in untreated CLL/SLL patients, with no new safety signals.